Ozben Beste, Erdogan Okan
Department of Cardiology, Marmara University School of Medicine, Istanbul, Turkey.
Inflamm Allergy Drug Targets. 2008 Sep;7(3):136-44. doi: 10.2174/187152808785748128.
It is well known that inflammatory mechanisms play a crucial role in the pathogenesis of atherosclerosis and coronary artery disease. In recent years, allergic episodes have been shown to be associated with acute coronary syndromes. Mast cells release certain inflammatory mediators including histamine and neutral proteases during an allergic episode and these inflammatory mediators are implied to induce coronary artery spasm and/or atheromatous plaque erosion or rupture. As the inflammatory component of acute coronary syndromes is a potential therapeutic target, drugs that stabilize mast cell membrane and monoclonal antibodies that protect mast cell surface may be effective in preventing allergy associated acute coronary syndromes. In this review, we will mention the role of inflammation and allergy and anti-inflammatory therapeutic modalities in acute coronary syndromes.
众所周知,炎症机制在动脉粥样硬化和冠状动脉疾病的发病机制中起着关键作用。近年来,过敏发作已被证明与急性冠状动脉综合征有关。肥大细胞在过敏发作期间释放某些炎症介质,包括组胺和中性蛋白酶,这些炎症介质被认为可诱发冠状动脉痉挛和/或动脉粥样斑块糜烂或破裂。由于急性冠状动脉综合征的炎症成分是一个潜在的治疗靶点,稳定肥大细胞膜的药物和保护肥大细胞表面的单克隆抗体可能对预防与过敏相关的急性冠状动脉综合征有效。在这篇综述中,我们将提及炎症和过敏以及抗炎治疗方式在急性冠状动脉综合征中的作用。